Actively Recruiting
SELUTION4BTK Trial
Led by M.A. Med Alliance S.A. · Updated on 2026-04-28
376
Participants Needed
48
Research Sites
532 weeks
Total Duration
On this page
Sponsors
M
M.A. Med Alliance S.A.
Lead Sponsor
N
NAMSA
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.
CONDITIONS
Official Title
SELUTION4BTK Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Life expectancy of at least 1 year
- Documented chronic limb-threatening ischemia in the target limb with Rutherford category 4 or 5 and symptoms lasting more than 2 weeks
- Able and willing to give written informed consent and comply with study procedures and follow-up
- Female participants of childbearing potential must be non-breastfeeding and have a negative pregnancy test within 7 days before the procedure
- Target lesion(s) must be new or non-stented restenotic lesions located in below-the-knee arteries distal to the tibial plateau and above the tibiotalar joint
- Target lesions must have at least 70% diameter narrowing by visual estimate and be suitable for balloon angioplasty treatment
- Target vessel diameter between 2mm and 4mm, with balloon size not exceeding 4.0 mm
- Target lesions confined to a single vessel; other non-target lesions must be successfully treated
- Target lesion length at least 30 mm and total treatment length no more than 150 mm
- Distal runoff vessels must be patent or reconstituted as specified for each artery
- No significant inflow vessel disease or successfully treated inflow disease
- Successful lesion preparation with less than or equal to 30% residual narrowing and no flow-limiting dissection before randomization
You will not qualify if you...
- Extensive tissue loss (Rutherford category 6) above the trans metatarsal level requiring complex foot reconstruction
- Chronic renal insufficiency with dialysis dependence or GFR less than or equal to 30 ml/min/1.73 m2 within 30 days or previous renal transplant
- Acute renal insufficiency within 48 hours before procedure
- Acute limb ischemia with symptoms less than 2 weeks prior
- Neuropathic, non-ischemic, venous, or mixed wounds
- Prior major amputation or planned major amputation of the target or either leg
- Target limb iliac or common femoral artery bypass within 6 weeks
- Recent or planned surgical or endovascular procedures within specified time frames except permitted procedures
- Prior treatment of target lesion with drug-coated balloon within 1 year or any prior stent treatment unless lesion is far from stent and low stenosis
- Target lesions requiring alternative therapies like thrombolysis or stenting
- Treatment via pedal or upper extremity access
- Recent non-coronary artery treatment with drug-coated devices within 3 months
- Known allergy to Sirolimus or required pharmacologic agents
- Contraindication to antiplatelet therapy
- Recent disabling stroke or heart attack within 3 months
- Acute coronary syndrome (stabilized allowed)
- Non-atherosclerotic disease of the target vessel
- Hypercoagulable disorders or low platelet count
- Systemic infection with fever and high white blood count
- Known immune compromise or immunosuppressive therapy (except topical corticosteroids)
- Current or planned cancer treatment or metastatic cancer (local creams allowed)
- New York Heart Association class IV heart failure
- Bedridden status
- Body mass index under 18
- Participation in another ongoing investigational drug or device study
- Other conditions limiting study participation or follow-up
- Presence of previously placed stent in target vessel unless lesion is distant and low stenosis
- Significant inflow disease in common femoral or profunda femoris arteries
- Unsuccessful lesion pre-dilatation
- Presence of intra-arterial thrombus or embolism
- Need for treatment of arteries below the tibiotalar joint or pedal arteries; angioplasty below this joint not permitted
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 48 locations
1
Chandler Regional Medical Center
Chandler, Arizona, United States, 85297
Actively Recruiting
2
St. Bernards Medical Center
Jonesboro, Arkansas, United States, 72401
Actively Recruiting
3
Arkansas Heart Hospital
Little Rock, Arkansas, United States, 72211
Terminated
4
St. Helena Hospital
St. Helena, California, United States, 94574
Terminated
5
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Torrance, California, United States, 90502
Actively Recruiting
6
ClinRé
Thornton, Colorado, United States, 80023
Terminated
7
Vascular Care Group
Darien, Connecticut, United States, 06820
Actively Recruiting
8
Yale University
New Haven, Connecticut, United States, 06519
Actively Recruiting
9
The Cardiac and Vascular Institute Research Foundation
Gainesville, Florida, United States, 32605
Actively Recruiting
10
Palm Vascular Centers
Miami, Florida, United States, 33141
Actively Recruiting
11
Guardian Research Organization, LLC
Winter Park, Florida, United States, 32792
Actively Recruiting
12
Cardiovascular Consultants of South Georgia
Thomasville, Georgia, United States, 31792
Terminated
13
Rush University Medical Center
Chicago, Illinois, United States, 60612
Actively Recruiting
14
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States, 60068
Actively Recruiting
15
Cardiovascular Institute of the South
Gray, Louisiana, United States, 70359
Actively Recruiting
16
MedStar Health Research Institute
Hyattsville, Maryland, United States, 20782
Actively Recruiting
17
Beth Israel Medical Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
18
University of Massachusetts Medical Center
Worcester, Massachusetts, United States, 01655
Actively Recruiting
19
Sorin Medical Group
New York, New York, United States, 10005
Actively Recruiting
20
NC Heart and Vascular Research, LLC
Raleigh, North Carolina, United States, 27607
Actively Recruiting
21
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
22
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Actively Recruiting
23
Hightower Clinical Research
Oklahoma City, Oklahoma, United States, 73134
Actively Recruiting
24
Miriam Hospital
Providence, Rhode Island, United States, 02906
Actively Recruiting
25
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
26
Tennessee Center for Clinical Trials
Tullahoma, Tennessee, United States, 37388
Suspended
27
El Paso Cardiology
El Paso, Texas, United States, 79912
Actively Recruiting
28
Baylor College of Medicine
Houston, Texas, United States, 77030
Actively Recruiting
29
Texas Cardiac and Vascular Institute San Antonio
San Antonio, Texas, United States, 78229
Actively Recruiting
30
Christus Health
Tyler, Texas, United States, 75702
Actively Recruiting
31
LKH-Universitätsklinikum Graz
Graz, Austria, A-8036
Actively Recruiting
32
Ambroise Paré Hospital
Boulogne-Billancourt, France, 92100
Actively Recruiting
33
Hôpital St. Joseph
Paris, France, 75014
Actively Recruiting
34
Alexianer Klinikum Hochsauerland
Arnsberg, Germany, 59759
Actively Recruiting
35
Universitäts-Herzzentrum Freiburg - Bad Krozingen
Bad Krozingen, Germany, 79189
Actively Recruiting
36
Krankenhaus Buchholz
Buchholz, Germany, 21244
Actively Recruiting
37
Sana Kliniken Oberfranken Coburg
Coburg, Germany, 96450
Actively Recruiting
38
University of Essen
Essen, Germany, 45147
Actively Recruiting
39
Universitatsklinikum Tubingen
Tübingen, Germany
Actively Recruiting
40
Queen Mary Hospital
Hong Kong, Pok Fu Lam, Hong Kong
Actively Recruiting
41
The Chinese University of Hong Kong
Hong Kong, Shatin, Hong Kong
Actively Recruiting
42
Ospedale Pederzoli
Peschiera del Garda, Verona, Italy, 37019
Actively Recruiting
43
UGC - Maria Cecilia Hospital
Cotignola, Italy, 48033
Actively Recruiting
44
Ospedale Policlinico San Martino
Genova, Italy, 16132
Terminated
45
St. Antonius Hospital
Nieuwegein, Netherlands, 3435 CM
Actively Recruiting
46
Auckland City Hospital
Auckland, New Zealand, 1023
Actively Recruiting
47
Singapore General Hospital
Singapore, Singapore, 169856
Actively Recruiting
48
Inselspital Bern
Bern, Switzerland
Terminated
Research Team
K
Kara Piscani
CONTACT
T
Tamarah Suys
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here